Theophylline in chronic obstructive pulmonary disease: New horizons

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 334-339

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Alveolar macrophage; Histone acetylation; Histone deacetylase; Oxidative stress; Phosphodiesterase

Indexed keywords

ADENOSINE RECEPTOR; CIMETIDINE; CORTICOSTEROID; FLUVOXAMINE; HISTONE DEACETYLASE; MACROLIDE; PHOSPHODIESTERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ABDOMINAL DISCOMFORT; ANTIINFLAMMATORY ACTIVITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONVULSION; DEACETYLATION; DIURESIS; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; NAUSEA; OXIDATIVE STRESS; RESTLESSNESS; SIDE EFFECT; STOMACH ACID SECRETION; VOMITING;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE; ENZYME ACTIVATION; HISTONE DEACETYLASES; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 28244462817     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200504-024SR     Document Type: Conference Paper

References (59)

1. Vignola AM. PDE4 inhibitors in COPD: a more selective approach to treatment. Respir Med 2004;98:495-503.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management of chronic obstructive pulmonary disease: NHLBI/WHO Workshop Report 2003. Available at URL www.goldcopd.com/workshop/ index.html [accessed August 2005].
3. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004;364:791-802.
4. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350:2689-2697.
5. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-1670.
6. Kirsten DK, Wegner RE, Jörres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993;104:1101-1107.
7. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airway disease. BMJ 1988;297:1506-1510.
8. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003;327:643.
9. Finney MJB, Karlson JA, Persson CGA. Effects of bronchoconstriction and bronchodilators on a novel human small airway preparation. Br J Pharmacol 1985;85:29-36.
10. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995;8:637-642.
11. Miura M, Belvisi MG, Stretton CD, Yacoub MH, Barnes PJ. Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis 1992;146:132-136.
12. Guillot C, Fornaris M, Badier M, Orehek J. Spontaneous and provoked resistance to isoproterenol in isolated human bronchi. J Allergy Clin Immunol 1984;74:713-718.
13. Hansel TT, Tennant RC, Tan AJ, Higgins LA, Neighbour H, Erin EM, Barnes PJ. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. Drugs Today 2004;40:55-69. Available at URL http://www.prous.com/journals/dot/20003612/index. cfm [accessed August 2005].
14. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-818.
15. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-1376.
16. Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M, Takamura K, Nagai K, Hosokawa T, Nishimura M. Effect of low-dose theophylline on airway inflammation in COPD. Respirology 2004;9:249-254.
17. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-548.
18. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-1639.
19. Loppow D, Schleiss MB, Kanniess F, Taube C, Jörres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-121.
20. Polson JB, Kazanowski JJ, Goldman AL, Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 1978;5:535-539.
21. Pauwels RA, Joos GF. Characterization of the adenosine receptors in the airways. Arch Int Pharmacodyn Ther 1995;329:151-160.
22. Björck T, Gustafsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992;145:1087-1091.
23. Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998;19:148-153.
24. Inbe H, Watanabe S, Miyawaki M, Tanabe E, Encinas JA. Identification and characterization of a cell-surface receptor, P2Y15, for AMP and adenosine. J Biol Chem 2004;279:19790-19799.
25. Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K, Okamura K. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999;14:309-314.
26. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34-38.
27. Oliver B, Tomita K, Keller A, Caramori G, Adcock I, Chung KF, Barnes PJ, Lim S. Low-dose theophylline does not exert its anti-inflammatory effects in mild asthma through upregulation of interleukin-10 in alveolar macrophages. Allergy 2001;56:1087-1090.
28. Tomita K, Chikumi H, Tokuyasu H, Yajima H, Hitsuda Y, Matsumoto Y, Sasaki T. Functional assay of NF-κB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Naunyn Schmiedebergs Arch Pharmacol 1999;359:249-255.
29. Ichiyama T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S. Theophylline inhibits NF-κB activation and IκBα degradation in human pulmonary epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 2001;364:558-561.
30. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on p110δ and other phosphoinositide 3-kinases: differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002;277:37124-37130.
31. phox by controlling cPKC/PKCδ but not Akt. Biochem Biophys Res Commun 2004;316:720-730.
32. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997;100:1677-1684.
33. Chung IY, Nam-Kung EK, Lee NM, Chang HS, Kim DJ, Kim YH, Park CS. The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. Cell Immunol 2000;203:95-102.
34. Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Nakazawa T, Komiyama A. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 2000;67:529-535.
35. Ohta K, Yamashita N. Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999;104:14-21.
36. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001;20:2991-3006.
37. Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, Ciaccia A, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003;58:348-351.
38. Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Gnemmi I, Ioli F, Chung KF, Donner CF, Barnes PJ, et al. Increased expression of NF-κB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002;20:556-563.
39. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749.
40. Thiagalingam S, Cheng K-H, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003;983:84-100.
41. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392-396.
42. To Y, Elliott WM, Ito M, Hayashi S, Adcock IM, Hogg JC, Barnes PJ, Ito K. Total histone deacetylase activity decreases with increasing clinical stage of COPD. Am J Respir Crit Care Med 2004;169:A276.
43. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625-636.
44. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-6903.
45. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139:359-370.
46. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733.
47. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004;315:240-245.
48. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99:8921-8926.
49. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-695.
50. Waterborg JH. Steady-state levels of histone acetylation in Saccharomyces cerevisiae. J Biol Chem 2000;275:13007-13011.
51. Ito K, Lim S, Chung KF, Barnes PJ, Adcock IM. Theophylline enhances histone deacetylase activity and restores glucocorticoid function during oxidative stress. Am J Respir Crit Care Med 2002;165:A625.
52. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-1418.
53. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-2760.
54. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-276.
55. Culpitt SV, Rogers DF, Shah P, de Matos C, Russell REK, Donnelly LE, Barnes PJ. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:24-31.
56. Barnes PJ. Current therapies for asthma: promise and limitations. Chest 1997;111:17S-26S.
57. Zhang Z-Y, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995;50:205-211.
58. Howell RE, Muehsam WT, Kinnier WJ. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 1990;46:563-568.
59. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364:985-996.